Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Redefining CAR-T Speed and Strength with DAR-T™: A Conversation with Nicholas Kirian
In this Q&A, Nicholas Kirian, Senior Manager of MSAT, discusses how DAR-T™, an autologous CAR-T platform, is addressing longstanding challenges in...
Presentation: Rapid Multi-Omics Cell Therapy Characterization and QC
On February 5th at 1:00 pm, join Neeraj Salathia, Director of Advanced Genomics, for a presentation on Rapid Multi-Omics Cell Therapy...
Whitepaper: 3-Day Short Cycle CAR-T Manufacturing Process
The conventional manufacturing process for the generation of activated CAR-T cells can typically take 7 to 9 days or even longer. Resilience has...
Presentation: Expedited Cell Therapy QC: Sample in, to QC Report in 48 Hours
On January 22nd at 4:00 pm, join Mazen Karaman, Director of Platform Management – Cell Therapy, for a presentation on Expedited Cell Therapy QC.
Boston, MA: Process & Analytical Development and Manufacturing Facility
The launch of our Process & Analytical Development and Manufacturing Facility marks a strategic resurgence in the Boston area, as we consolidate and...
On-Demand Presentation: Improving cell line development in CHO with a focus on product manufacturability
With a discussion on cell line productivity and evolution, an exploration of the benefits of utilizing molecule optimization and engineering, and an...
